Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2022 09:00 ET | Source: Silo Pharma, Inc.

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine

ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
November 21, 2022 07:45 ET | Source: Silo Pharma, Inc.

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...
November 11, 2022 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 26, 2022 09:00 ET | Source: Silo Pharma, Inc.

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

ENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 20, 2022 08:05 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 18, 2022 07:15 ET | Source: Silo Pharma, Inc.

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 10, 2022 08:05 ET | Source: Silo Pharma, Inc.

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Silo...
October 06, 2022 08:20 ET | Source: Silo Pharma, Inc.

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) --...
October 03, 2022 09:47 ET | Source: Silo Pharma, Inc.

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
September 30, 2022 08:30 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...